1. Home
  2. YHGJ vs SNGX Comparison

YHGJ vs SNGX Comparison

Compare YHGJ & SNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Yunhong Green CTI Ltd.

YHGJ

Yunhong Green CTI Ltd.

HOLD

Current Price

$3.00

Market Cap

11.2M

Sector

Industrials

ML Signal

HOLD

Logo Soligenix Inc.

SNGX

Soligenix Inc.

HOLD

Current Price

$1.22

Market Cap

12.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
YHGJ
SNGX
Founded
1975
1987
Country
United States
United States
Employees
N/A
N/A
Industry
Specialty Chemicals
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.2M
12.0M
IPO Year
2006
2006

Fundamental Metrics

Financial Performance
Metric
YHGJ
SNGX
Price
$3.00
$1.22
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
5.3K
111.5K
Earning Date
04-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$17,953,000.00
$119,371.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
0.84
N/A
52 Week Low
$0.47
$1.02
52 Week High
$10.29
$6.23

Technical Indicators

Market Signals
Indicator
YHGJ
SNGX
Relative Strength Index (RSI) 47.60 51.83
Support Level $2.45 $1.19
Resistance Level $3.03 $1.22
Average True Range (ATR) 0.26 0.06
MACD 0.06 0.01
Stochastic Oscillator 51.38 54.35

Price Performance

Historical Comparison
YHGJ
SNGX

About YHGJ Yunhong Green CTI Ltd.

Yunhong Green CTI Ltd manufactures and marketers of foil balloons and produces laminated and printed films for commercial uses. The company also distributes balloon-inspired and other gift items, and continues development of compostable material solutions, and markets its products throughout the United States and in several other countries.

About SNGX Soligenix Inc.

Soligenix Inc is a late-stage biopharmaceutical company based in the United States. It focuses on developing and commercializing products to treat rare diseases where there is an unmet medical need. The company operates through two business segments namely Specialized BioTherapeutics and Public Health Solutions. It generates maximum revenue from Public Health Solutions with active development programs for RiVax, its ricin toxin vaccine candidate, SGX943, its therapeutic candidate for antibiotic resistant and emerging infectious disease, and its research programs to identify and develop novel vaccine candidates targeting viral infection including Ebola, Marburg and SARS-CoV-2 (the cause of COVID-19).

Share on Social Networks: